**Common Drug Review**

**Product:** Humira  
**Generic Name:** adalimumab  
**Manufacturer:** Abbott Laboratories, Limited  
**Submission Type:** Resubmission #2

<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Time (Business Days)</th>
<th>Target Date**</th>
<th>Actual CDR Date</th>
<th>Comments</th>
</tr>
</thead>
</table>
| 1     | Submission Assessment       | 5             | 2006-Nov-24     | Submission deemed complete  
| 2     | CDR Reviewers' Reports Completed  
|       | • Reviewers selected and contracted  
|       | • Literature search and selection completed  
|       | • Systematic review of clinical data completed  
|       | • Critical appraisal of pharmacoeconomic (PE) data completed  
|       | • Clinical and PE reports written  
|       | • Reports edited and finalized  
|       | | | | Additional information received January 11, 2007.  
|       | | | | Additional information received January 24, 2007.  
|       | | | | Additional information requested February 7, 2007.  
|       | | | | Additional information received February 14, 2007.  
|       | | | | Additional information received February 19, 2007.  
|       | | | | Additional information requested February 20, 2007.  
|       | | | | Additional information received March 1, 2007.  
|       | | | | Additional information received March 2, 2007.  
| 3     | Comments from Manufacturer on Reviewers' Reports Received by CDR | 7 | 2007-Mar-07 | 2007-Mar-14 | Due date for manufacturer's comments March 14, 2007.  
| 5     | CEDAC Brief Completed and Sent to CEDAC Members | 5 | 2007-Apr-03 | 2007-Apr-03 |  
| 6     | CEDAC Meeting | | 2007-Apr-18 | 2007-Apr-18 |  
| 7     | CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer | 5 | 2007-Apr-25 | 2007-Apr-26 |  
|       | Request for extension of Embargo period received on May 4, 2007.  
|       | Extension to May 18, 2007 granted.  
|       | Request for reconsideration received May 17, 2007.  
| 9 (a) | Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is resolved) | 5 | | |  
| 9 (b) | Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made) | | | |  
| 9 (c) | Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request) | 25 | Depends on Meeting Dates | 2007-Jun-20 | 2007-Jun-20 |  

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.  
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.  
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation. Reflects updates as of Thursday noon.